Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

Completed · Phase 2

Conditions studied: Schizophrenia

In brief

The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.

Key facts

Study ID

NCT02288845

Run by

Intra-Cellular Therapies, Inc.

People needed

14

Starts

2014-10-01

Expected to finish

2015-09-01

Last updated by the study team

2017-03-10

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with schizophrenia who are drug-free with regard to their antipsychotic medication
• In clinical remission and free from acute exacerbation of their psychosis
• In good health

You may not qualify if…

• Clinically significant medical conditions considered inappropriate for trial participation

Where it is running

• Johns Hopkins Medical Institutions — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.